IPSEN - Buy-back programme - Art 5 of MAR - Week 44 - 2023

IPSEN – Buy-back programme – Art 5 of MAR – Week 44 – 2023

Back

IPSEN – Buy-back programme – Art 5 of MAR – Week 44 – 2023

- 07 November 2023 - 1 mins read
Statement of transactions in own shares from October 30 to November 03, 2023 BNP PARIBAS
Aggregated presentation by day and by market
Name of issuer Identification code of issuer (Legal Entity Identifier) Day of transaction Identification code of financial instrument Aggregated daily volume (in number of shares) Daily weighted average price of the purchased shares * Market (MIC Code)
IPSEN 549300M6SGDPB4Z94P11 30/10/2023 FR0010259150 22 111.80 AQEU
IPSEN 549300M6SGDPB4Z94P11 30/10/2023 FR0010259150 240 111.70 CEUX
IPSEN 549300M6SGDPB4Z94P11 30/10/2023 FR0010259150 41 111.90 TQEX
IPSEN 549300M6SGDPB4Z94P11 30/10/2023 FR0010259150 1,908 111.83 XPAR
IPSEN 549300M6SGDPB4Z94P11 31/10/2023 FR0010259150 41 112.10 AQEU
IPSEN 549300M6SGDPB4Z94P11 31/10/2023 FR0010259150 161 112.80 CEUX
IPSEN 549300M6SGDPB4Z94P11 31/10/2023 FR0010259150 226 112.70 TQEX
IPSEN 549300M6SGDPB4Z94P11 31/10/2023 FR0010259150 2,572 112.95 XPAR
IPSEN 549300M6SGDPB4Z94P11 01/11/2023 FR0010259150 182 112.72 AQEU
IPSEN 549300M6SGDPB4Z94P11 01/11/2023 FR0010259150 286 112.96 CEUX
IPSEN 549300M6SGDPB4Z94P11 01/11/2023 FR0010259150 47 112.94 TQEX
IPSEN 549300M6SGDPB4Z94P11 01/11/2023 FR0010259150 2,485 112.84 XPAR
IPSEN 549300M6SGDPB4Z94P11 02/11/2023 FR0010259150 289 112.09 AQEU
IPSEN 549300M6SGDPB4Z94P11 02/11/2023 FR0010259150 165 112.57 CEUX
IPSEN 549300M6SGDPB4Z94P11 02/11/2023 FR0010259150 92 112.05 TQEX
IPSEN 549300M6SGDPB4Z94P11 02/11/2023 FR0010259150 2,454 112.68 XPAR
IPSEN 549300M6SGDPB4Z94P11 03/11/2023 FR0010259150 162 110.80 AQEU
IPSEN 549300M6SGDPB4Z94P11 03/11/2023 FR0010259150 94 110.93 CEUX
IPSEN 549300M6SGDPB4Z94P11 03/11/2023 FR0010259150 4 110.70 TQEX
IPSEN 549300M6SGDPB4Z94P11 03/11/2023 FR0010259150 2,740 111.09 XPAR
* Two-digit rounding after the decimal TOTAL 14,211 112.27

Attachment

Related Press Releases

Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential
11 July 2024 6 mins read

Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential
IPSEN – Buy-back programme – Art 5 of MAR – Week 27 – 2024
09 July 2024 1 mins read

IPSEN – Buy-back programme – Art 5 of MAR – Week 27 – 2024
Ipsen – June 2024 – Monthly information relative to the total number of voting rights and shares composing the share capital
09 July 2024 1 mins read

Ipsen – June 2024 – Monthly information relative to the total number of voting rights and shares composing the share capital
Half-year statement of IPSEN liquidity agreement – 2024 06 30
08 July 2024 1 mins read

Half-year statement of IPSEN liquidity agreement – 2024 06 30
IPSEN – Buy-back programme – Art 5 of MAR – Week 26 – 2024
02 July 2024 1 mins read

IPSEN – Buy-back programme – Art 5 of MAR – Week 26 – 2024
Ipsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroendocrine tumors based on positive CABINET Phase III trial
02 July 2024 9 mins read

Ipsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroendocrine tumors based on positive CABINET Phase III trial
IPSEN – Buy-back programme – Art 5 of MAR – Week 25 – 2024
25 June 2024 1 mins read

IPSEN – Buy-back programme – Art 5 of MAR – Week 25 – 2024
IPSEN – Buy-back programme – Art 5 of MAR – Week 24 – 2024
18 June 2024 1 mins read

IPSEN – Buy-back programme – Art 5 of MAR – Week 24 – 2024
IPSEN – Buy-back programme – Art 5 of MAR – Week 23 – 2024
11 June 2024 1 mins read

IPSEN – Buy-back programme – Art 5 of MAR – Week 23 – 2024
Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis
10 June 2024 12 mins read

Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis